173 related articles for article (PubMed ID: 34907909)
1. WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.
Kishikawa T; Higuchi H; Wang L; Panch N; Maymi V; Best S; Lee S; Notoya G; Toker A; Matesic LE; Wulf GM; Wei W; Otsuka M; Koike K; Clohessy JG; Lee YR; Pandolfi PP
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34907909
[TBL] [Abstract][Full Text] [Related]
2. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.
Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP
N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922
[TBL] [Abstract][Full Text] [Related]
3. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.
Clement E; Inuzuka H; Nihira NT; Wei W; Toker A
Sci Signal; 2018 Mar; 11(521):. PubMed ID: 29535262
[TBL] [Abstract][Full Text] [Related]
4. The WWP1 ubiquitin E3 ligase increases TRAIL resistance in breast cancer.
Zhou Z; Liu R; Chen C
Int J Cancer; 2012 Apr; 130(7):1504-10. PubMed ID: 21480222
[TBL] [Abstract][Full Text] [Related]
5. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
[TBL] [Abstract][Full Text] [Related]
6. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
7. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
8. The amplified WWP1 gene is a potential molecular target in breast cancer.
Chen C; Zhou Z; Ross JS; Zhou W; Dong JT
Int J Cancer; 2007 Jul; 121(1):80-87. PubMed ID: 17330240
[TBL] [Abstract][Full Text] [Related]
9. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
11. WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells.
Yeung B; Ho KC; Yang X
PLoS One; 2013; 8(4):e61027. PubMed ID: 23573293
[TBL] [Abstract][Full Text] [Related]
12. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
13. The ubiquitin E3 ligase WWP1 decreases CXCL12-mediated MDA231 breast cancer cell migration and bone metastasis.
Subik K; Shu L; Wu C; Liang Q; Hicks D; Boyce B; Schiffhauer L; Chen D; Chen C; Tang P; Xing L
Bone; 2012 Apr; 50(4):813-23. PubMed ID: 22266093
[TBL] [Abstract][Full Text] [Related]
14. The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11.
Chen C; Zhou Z; Liu R; Li Y; Azmi PB; Seth AK
Oncogene; 2008 Nov; 27(54):6845-55. PubMed ID: 18724389
[TBL] [Abstract][Full Text] [Related]
15. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.
Zhang H; Chen D; Ringler J; Chen W; Cui QC; Ethier SP; Dou QP; Wu G
Cancer Res; 2010 May; 70(10):3996-4004. PubMed ID: 20424113
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin Ligase Activities of WWP1 Germline Variants K740N and N745S.
Jiang H; Dempsey DR; Cole PA
Biochemistry; 2021 Feb; 60(5):357-364. PubMed ID: 33470109
[TBL] [Abstract][Full Text] [Related]
18. WWP2 is a physiological ubiquitin ligase for phosphatase and tensin homolog (PTEN) in mice.
Li H; Zhang P; Zhang Q; Li C; Zou W; Chang Z; Cui CP; Zhang L
J Biol Chem; 2018 Jun; 293(23):8886-8899. PubMed ID: 29685889
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
[TBL] [Abstract][Full Text] [Related]
20. E3 ubiquitin ligase, WWP1, interacts with AMPKα2 and down-regulates its expression in skeletal muscle C2C12 cells.
Lee JO; Lee SK; Kim N; Kim JH; You GY; Moon JW; Jie S; Kim SJ; Lee YW; Kang HJ; Lim Y; Park SH; Kim HS
J Biol Chem; 2013 Feb; 288(7):4673-80. PubMed ID: 23293026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
